| Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation JNHG Ho, D Schmidt, T Lowinus, J Ryoo, EP Dopfer, N Gonzalo Núñez, ... Blood, The Journal of the American Society of Hematology 140 (10), 1167-1181, 2022 | 34 | 2022 |
| Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency JS Heitmann, C Tandler, M Marconato, A Nelde, T Habibzada, SM Rittig, ... Nature Communications 14 (1), 5032, 2023 | 16 | 2023 |
| Identification of CD105 (endoglin) as novel risk marker in CLL SM Greiner, M Märklin, S Holzmayer, K Kaban, S Meyer, C Hinterleitner, ... Annals of Hematology 101 (4), 773-780, 2022 | 6 | 2022 |
| Immunoprofiling of 4-1BB expression predicts outcome in chronic lymphocytic leukemia (CLL) K Kaban, SM Greiner, S Holzmayer, C Tandler, S Meyer, C Hinterleitner, ... Diagnostics 11 (11), 2041, 2021 | 4 | 2021 |
| Targeting NKG2DL with Bispecific NKG2D–CD16 and NKG2D–CD3 Fusion Proteins on Triple–Negative Breast Cancer P Kaidun, SJ Holzmayer, SM Greiner, A Seller, CM Tegeler, I Hagelstein, ... International Journal of Molecular Sciences 24 (17), 13156, 2023 | 3 | 2023 |
| NK cell immunosurveillance of tumors is regulated by NFAT1 and NFAT2 M Märklin, S Holzmayer, K Kaban, MR Mueller, HR Salih Cancer Research 82 (12_Supplement), 2104-2104, 2022 | 2 | 2022 |
| Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody SA Stefańczyk, I Hagelstein, MS Lutz, S Müller, SJ Holzmayer, G Jarjour, ... Blood Cancer Journal 14 (1), 67, 2024 | 1 | 2024 |
| Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency J Walz, J Heitmann, C Tandler, M Marconato, T Habibzade, S Rittig, ... | 1 | 2022 |
| The bispecific B7H3xCD3 antibody CC-3 induces T cell immunity against bone and soft tissue sarcomas SJ Holzmayer, K Liebel, I Hagelstein, HR Salih, M Märklin Frontiers in Immunology 15, 1391954, 2024 | | 2024 |
| Asciminib Maintains Antibody-Dependent Cellular Cytotoxicity against Leukemic Blasts SJ Holzmayer, J Kauer, J Mauermann, T Roider, M Märklin Cancers 16 (7), 1288, 2024 | | 2024 |
| Crosstalk between NFAT and NFκB Signaling Regulates NK Cell Immunosurveillance M Märklin, S Holzmayer, MR Mueller, HR Salih Blood 142 (Supplement 1), 1183-1183, 2023 | | 2023 |
| 965 NFAT2 drives the cytoskeletal remodeling of leukemia cells, which regulates their vulnerability to perforin-mediated killing S Holzmayer, J Mauermann, SM Greiner, JS Heitmann, K Kaban, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| NFAT2 determines susceptibility of chronic lymphocytic leukemia cells to constitutive and Rituximab-induced NK cell killing SJ Holzmayer, SM Greiner, K Kaban, JS Heitmann, HR Salih, M Maerklin Cancer Research 82 (12_Supplement), 2102-2102, 2022 | | 2022 |
